| Literature DB >> 22434850 |
Ian R Monk1, Ishita M Shah, Min Xu, Man-Wah Tan, Timothy J Foster.
Abstract
UNLABELLED: The strong restriction barrier present in Staphylococcus aureus and Staphylococcus epidermidis has limited functional genomic analysis to a small subset of strains that are amenable to genetic manipulation. Recently, a conserved type IV restriction system termed SauUSI (which specifically recognizes cytosine methylated DNA) was identified as the major barrier to transformation with foreign DNA. Here we have independently corroborated these findings in a widely used laboratory strain of S. aureus. Additionally, we have constructed a DNA cytosine methyltransferase mutant in the high-efficiency Escherichia coli cloning strain DH10B (called DC10B). Plasmids isolated from DC10B can be directly transformed into clinical isolates of S. aureus and S. epidermidis. We also show that the loss of restriction (both type I and IV) in an S. aureus USA300 strain does not have an impact on virulence. Circumventing the SauUSI restriction barrier, combined with an improved deletion and transformation protocol, has allowed the genetic manipulation of previously untransformable strains of these important opportunistic pathogens. IMPORTANCE: Staphylococcal infections place a huge burden on the health care sector due both to their severity and also to the economic impact of treating the infections because of prolonged hospitalization. To improve the understanding of Staphylococcus aureus and Staphylococcus epidermidis infections, we have developed a series of improved techniques that allow the genetic manipulation of strains that were previously refractory to transformation. These developments will speed up the process of mutant construction and increase our understanding of these species as a whole, rather than just a small subset of strains that could previously be manipulated.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22434850 PMCID: PMC3312211 DOI: 10.1128/mBio.00277-11
Source DB: PubMed Journal: MBio Impact factor: 7.867
FIG 1 Transformation of S. aureus Newman and isogenic mutants defective in restriction. Concentrated pRMC2 DNA (5 µg) isolated from S. aureus Newman, E. coli BW25113 (dam+ dcm+), or E. coli IBEC55 (dam+) were electroporated into Newman or Newman restriction mutants. The transformation efficiency was expressed as the mean number of all transformants obtained in each experiment ± standard deviation (error bar) of three replicates. The graph shows data representative of the data from three independent experiments.
FIG 2 Genetic map of pIMAY. The E. coli/staphylococcal temperature-sensitive plasmid pIMAY comprises the low-copy-number E. coli origin of replication (p15A), an origin of transfer for conjugation (oriT), the pBluescript multiple cloning site (MCS), and the highly expressed cat gene (Phelp-cat) derived from pIMC (34). The temperature-sensitive replicon for Gram-positive bacteria (repBCAD) and the tetracycline-inducible antisense secY region (anti-secY) were amplified from pVE6007 (21) and pKOR1 (19), respectively. The restriction sites listed are unique. Primers (IM151/152) bind external to the MCS of pIMAY and are used to screen clones in E. coli (amplify 283 bp without a cloned insert) and to determine the presence of a replicating plasmid in staphylococci.
FIG 3 Schematic of allelic exchange with pIMAY. (A) A plasmid isolated from E. coli DC10B is transformed into staphylococci at 28°C, and single-crossover (SCO) integration was stimulated by growth at 37°C in the presence of chloramphenicol. The loss of replicating plasmid is assayed by colony PCR with MCS primers (IM151/IM152). Clones negative for replicating plasmid are then screened for the side of integration with a combination of chromosomal and cloning primers (e.g., OUT FWD/D REV [AB integration {AB INT}] or OUT REV/A FWD [CD integration {CD INT}]). The diagram details an integration event through the AB side (equivalent to clone h in panels B and C). A clone from either AB or CD integration event is grown at 28°C in broth without antibiotic selection to stimulate rolling circle replication and then plated on TSA with 1 µg/ml ATc. Expression of the secY antisense RNA (a-secY) inhibits growth of cells maintaining the plasmid. Plasmid excision through the AB side recreates the wild-type locus, while CD excision yields a mutated gene. (B) Colony PCR from 10 randomly chosen clones (clones a to j) after growth at 37°C for the presence of replicating plasmid. The absence of product indicates that the plasmid has integrated. Colony PCR from cells grown at 28°C is included as a positive control (+ve). (C) Two clones without replicating plasmid (clones c and h) were shown by colony PCR to have integrated either on the AB (upstream [clone h]) or CD (downstream [clone c]) side of the gene to be deleted. Wild-type (WT) genomic DNA was included as a control.
FIG 4 Assays for the activity of SauUSI. (A) The shuttle plasmid pRMC2 was isolated from isogenic E. coli methylation mutants and incubated in NEB ligation buffer with (+) or without (−) purified SauUSI-his for 1 h at 37°C. The DNA was then purified and run on a 1% agarose gel. The positions of linearized (6.4 kb) (L), relaxed circular (RC), covalently closed circular (CCC), and multimers (M) of pRMC2 are indicated by the black arrowheads to the right of the gel. (B) Concentrated pRMC2 DNA (5 µg) isolated from isogenic E. coli methylation mutants was electroporated into either S. aureus Newman or Newman ∆sauUSI mutant. The transformation efficiency was expressed as the total number of transformants obtained in each experiment ± standard deviation (error bar) of three replicates. The graph shows data representative of the data from three independent experiments.
FIG 5 Transformation of S. aureus Cowan, S. epidermidis RP62a, and S. aureus NRS384. pRMC2 DNA (5 µg) isolated from isogenic E. coli methylation mutants was electroporated into either the wild type or the corresponding ΔsauUSI or ΔmcrR mutant of the strain specified. The transformation efficiency is expressed as the total number of transformants obtained in each experiment with standard deviation of three replicates. An asterisk denotes that no transformants were detected.
FIG 6 Transformation of strains from a diverse selection of S. aureus sequence types and an S. epidermidis isolate. (A) Phylogenetic relatedness of the S. aureus strains selected for transformation, adapted from reference 35 with permission of the publisher. Representative sequence types used for transformation are highlighted in bold type. (B) Concentrated pRMC2 DNA (5 µg) isolated from E. coli DH10B (dam+ dcm+) or DC10B (dam+) was electroporated into strains from different S. aureus STs (denoted by the number on the x axis) including strains Cowan, MRSA252, N315, LAC, and S. epidermidis RP62a. The transformation efficiency was expressed as the total number of transformants obtained in each experiment ± standard deviation of three replicates. An asterisk denotes that no transformants were detected. The graph shows data from one experiment.
FIG 7 Transformation and virulence of restriction mutants of S. aureus USA300 strain NRS384. (A) PCR profiles (primers IM110/IM111) of the sauUSI region amplified from NRS384 (lanes 1), NRS384 hsdR (lanes 2), and NRS384 hsdR (lanes 3) without or with EcoRV digestion. (B) Concentrated pRMC2 DNA (5 µg) isolated from E. coli DH10B (dam+ dcm+) (light grey bars) or DC10B (dam+) (dark grey bars) was electroporated into the strains described above, and transformants were enumerated. (C) Intravenous injection of 2 × 106 CFU into 6- to 7-week-old female A/J mice. On day 7 of infection, the mice were euthanized, both kidneys were aseptically removed, and the bacterial CFU were enumerated as described in Materials and Methods. Each symbol represents the value for an individual mouse, and the short black line represents the mean for the group of mice. The broken line denotes the limit of detection at 333 CFU for the two kidneys.
Bacterial strains, plasmids, and oligonucleotides used in this study
| Bacterial strain, plasmid, or oligonucleotide | Description (relevant genotype or phenotype) or sequence ( | Source, reference, or RE site |
|---|---|---|
|
| ||
| DH10B (K-12 strain) |
| Invitrogen |
| BW25113 (K-12 strain) |
| 15 |
| IBEC55 | Δ | 15 |
| IBEC56 | Δ | 15 |
| IBEC57 | Δ | 15 |
| IBEC58 | Δ | 15 |
| DC10B | Δ | This study |
| BL21(DE3) (B strain) | F–
| Novagen |
|
| ||
| Newman | ST8; CC8 isolated in 1952 human clinical MSSA; genome sequenced | 4 |
| Newman Δ | Newman with a deletion of Sae0139 | This study |
| Newman Δ | Newman with a deletion of Sae2386 | This study |
| Newman Δ | Newman with a deletion of both Sae0139 and Sae2386 | This study |
| Newman Δ | Restoration of Sae2386 in the Δ | This study |
| Newman Δ | Newman with a deletion of Sae2385 | This study |
| NRS384 | USA300-14 clone obtained from NARSA | NARSA collection |
| NRS384 | Targetron insertion at nucleotide 735 of | This study |
| NRS384 | Targetron insertion at nucleotide 739 of | This study |
| NRS384 | Targetron insertion in | This study |
| NRS384 | Restoration of the | This study |
| RN4220 | ST8; CC8; chemically mutagenized derivative of 8325-4, transformable with | 11 |
| RN4220 | Nonsense mutation in | This study |
| Cowan | ST30; CC30 MSSA;high-level protein A producer; ATCC 12598 | 25 |
| Cowan Δ | Deletion of | This study |
| N315 | ST5 CC5 MSSA; genome sequenced | 29 |
| LAC | ST8 CC8 CA-MRSA; USA300 | 6 |
| MRSA252 | ST36 CC30 MRSA; genome sequenced | 36 |
| Oxford 13 | ST22 CC22 | 37 |
| Oxford 19 | ST10 CC16 | 37 |
| Oxford 71 | ST1 CC1 | 37 |
| Oxford 159 | ST25 CC25 | 37 |
| Oxford 207 | ST15 CC15 | 37 |
| Oxford 233 | ST45 CC45 | 37 |
| Oxford 560 | ST121 CC51 | 37 |
| Oxford 3177 | ST97 CC16 | 37 |
| RP62a | Methicillin-resistant, biofilm-forming | 24 |
| RP62a ∆ | Deletion of Serp2052; able to accept DNA at a low frequency from wild-type | This study |
|
| ||
| OG1RF | Rifampin- and fusic acid-resistant | 38 |
| JH2-2 | Rifampin- and fusic acid-resistant | 39 |
| V583 | Vancomycin-resistant clinical isolate of | 40 |
| Plasmids | ||
| pNL9164 | Temperature-sensitive targetron plasmid for | Sigma |
| pNL9164( | pNL9164 retargeted for | This study |
| pNL9164( | pNL9164 retargeted for | This study |
| pKD4 | Plasmid for amplification of | 26 |
| pKD46 |
| 26 |
| pCP20 |
| 10 |
| pIMC | Site-specific integrating vector; p15A low-copy-number origin of replication; RP4 conjugative origin of transfer and Phelp-driven chloramphenicol resistance marker; pBluescript MCS; Cmr | 34 |
| pKOR1 | Temperature-sensitive shuttle vector for allelic exchange in | 19 |
| pVE6007 | pWV01ts-derived plasmid that cannot replicate in | 21 |
| pIMC5 | Temperature-sensitive Gram-positive replicon from pVE6007 with an | This study |
| pIMAY | pIMC5 with tetracycline; inducible | This study |
| pIMAYΔ | A deletion encompassing the entire | This study |
| pIMAYΔ | A deletion encompassing the entire | This study |
| pIMAYΔ | A deletion encompassing the entire | This study |
| pIMAYΔ | A deletion encompassing the entire | This study |
| pIMAY | A silent EcoRV site was introduced into the middle of the | This study |
| pIMAY(RN4220 | A 1-kb fragment amplified from Newman surrounding the premature stop codon in RN4220 | This study |
| pIMAYΔ | A deletion encompassing the entire putative nudix gene (between the ATG and TAA codons); amplified from Newman (IM222/IM223/IM224/IM225) | This study |
| pET21d+ | C-terminal hexahistadine tagging vector; Ampr | Novagen |
| pET21d+ | The entire | This study |
| Oligonucleotides | ||
| IM46 (pVE6007 F) |
| SphI |
| IM47 (pVE6007 R) |
| |
| IM48 (pIMC F) |
| |
| IM49 (pIMC R) |
| BglII |
| IM72 (anti |
| BglII |
| IM73 (anti |
| SphI |
| IM93 (Δ |
| KpnI |
| IM2 (Δ |
| |
| IM3 (Δ |
| |
| IM94 (Δ |
| SacI |
| IM5 ( |
| |
| IM6 ( |
| |
| IM89 (Δ |
| KpnI |
| IM90 (Δ |
| |
| IM91 (Δ |
| |
| IM92 (Δ |
| SacI |
| IM150 (CC30 |
| SacI |
| IM110 ( |
| |
| IM111 ( |
| |
| IM108 (RN |
| KpnI |
| IM109 (RN |
| SacI |
| IM350 (384 |
| EcoRV |
| IM351 (384 |
| EcoRV |
| IM196 (His-SauUSI F) |
| NcoI |
| IM197 (His-SauUSI R) |
| XhoI |
| IM216 (Se Δ |
| SalI |
| IM217 (Se Δ |
| |
| IM218 (Se Δ |
| |
| IM219 (Se Δ |
| EcoRI |
| IM220 (Se |
| |
| IM221 (Se |
| |
| IM222 (Δ |
| KpnI |
| IM223 (Δ |
| |
| IM224 (Δ |
| |
| IM225 (Δ |
| SacI |
| IM226 ( |
| |
| IM227 ( |
| |
| IM261 (Ec Δ | ||
| IM262 (Ec Δ | ||
| IM251 (Ec Δ |
| |
| IM252 (Ec Δ |
| |
| IMS80 ( |
| HindIII |
| IMS81 ( |
| BsrGI |
| IMS82 ( |
| |
| IMS83 ( |
| |
| IMS84 ( |
| |
| IMS85 ( |
| HindIII |
| IMS86 ( |
| BsrGI |
| IMS87 ( |
| |
| IMS90 ( |
| |
| IMS91 ( |
| |
| IMSuni |
| |
| IM151 (pIMAY MCS F) |
| |
| IM152 (pIMAY MCS R) |
| |
S. aureus and S. epidermidis gene designations are taken from http://kegg.jp. For oligonucleotides, anti secY stands for antisense secY RNA.
The description (relevant genotype, phenotype, or other characteristic) is shown for bacterial strains and plasmids. MSSA, methicillin-sensitive S. aureus.
The primers used in the construction of recombinant plasmids are shown in parentheses at the end of the entry. The sequences for primers are shown. Restriction sites are indicated by underlining. Regions of homology for SOE PCR with the B primer are shown in italic type, and regions of homology for recombineering in E. coli are shown in bold type.
The source or reference is shown for bacterial strains and plasmids. The restriction enzyme (RE) site is shown for oligonucleotides.